RECURSION PHARMACEUTICALS INC. - CLASS A COMMON S

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

07 Jan 2025 08:15:00 By Nasdaq GlobeNewswire

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

06 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

20 Dec 2024 15:05:00 By Nasdaq GlobeNewswire

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

09 Dec 2024 17:00:00 By Nasdaq GlobeNewswire

Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma

03 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

20 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

Recursion and Exscientia Shareholders Approve the Proposed Combination

13 Nov 2024 08:08:19 By Nasdaq GlobeNewswire

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden

12 Nov 2024 15:54:03 By Nasdaq GlobeNewswire

Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results

06 Nov 2024 15:15:00 By Nasdaq GlobeNewswire

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

30 Oct 2024 07:22:19 By Nasdaq GlobeNewswire

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

22 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

02 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

03 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

08 Aug 2024 13:41:34 By Nasdaq GlobeNewswire

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

08 Aug 2024 06:39:25 By Nasdaq GlobeNewswire

Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

08 Aug 2024 06:30:30 By Nasdaq GlobeNewswire

Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT

08 Aug 2024 00:32:39 By Nasdaq GlobeNewswire

Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th

05 Aug 2024 15:01:00 By Nasdaq GlobeNewswire

Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock

26 Jun 2024 21:07:10 By Nasdaq GlobeNewswire

Recursion Announces Proposed Offering of Class A Common Stock

26 Jun 2024 15:06:32 By Nasdaq GlobeNewswire